Piper Jaffray & Co. reiterates an Overweight rating on Regeneron Pharmaceuticals (Nasdaq: REGN), raises price target from $19 to $22 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE